Developer docs
API playgroundTry for free, no card

Search company profiles

Concentric Analgesics

Full company profile

uuid0004xi5

Namestring
Concentric Analgesics
Legal namestring
Concentric Analgesics, Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Concentric Analgesics is a clinical-stage biopharmaceutical company developing a portfolio of non-opioid therapeutics for acute and chronic pain management. The company's scientific platform is built on novel TRPV1 agonist prodrug chemistry, in which water-soluble prodrugs are administered locally and then rapidly convert to capsaicin, a TRPV1 receptor agonist. The active metabolite selectively desensitizes pain-conducting C-fiber nociceptors, producing durable analgesia without the sensory numbness or motor weakness characteristic of local anesthetics or regional nerve blocks. The pipeline comprises three product candidates: vocacapsaicin (CA-008), the lead Phase 3-ready program targeting postsurgical pain via a single intraoperative injection with durable relief of two weeks or more; CA-051, an epidural formulation for chronic refractory cancer pain and post-amputation pain; and CA-011, an intra-articular injection targeting 3-6 months of relief in moderate-to-severe knee osteoarthritis, an addressable population of more than 14 million Americans.

Vocacapsaicin carries both FDA Fast Track Designation (December 2017) and FDA Breakthrough Therapy Designation (September 2018), and positive Phase 2 data have been generated across bunionectomy (33% pain reduction, 50% opioid consumption reduction), total knee arthroplasty (21% pain reduction, 31% opioid reduction through 168 hours, 52% opioid reduction after discharge), and open laparotomy indications. Phase 2 results were published on the cover of the August 2024 issue of ANESTHESIOLOGY. The company has formalized Phase 3 clinical partnerships with Evolution Research Group (a U.S. postsurgical pain site network) and the University of Rochester Medical Center for registration trials.

Concentric Analgesics operates a clinical-stage business model with no commercial revenue today; near-term economics depend on advancing vocacapsaicin through Phase 3, NDA filing, and eventual commercialization. Future commercialization is expected to follow an enterprise field sales model targeting hospitals, ambulatory surgical centers, anesthesiologists, and orthopedic surgeons for the postsurgical indication, with broader applicability to oncology pain management and osteoarthritis workflows. The company is headquartered in the San Francisco Bay Area, was founded in 2014 (per firmographic records) / 2017 (per company-history records), and has raised approximately $96 million in total equity and convertible financing from institutional investors including Oracle Investment Management, Venrock Healthcare Capital Partners, Cowen Healthcare Investments, Kern Whelan Capital, and Incisive Capital. Headcount is in the 11-50 range, consistent with a lean clinical-development-stage organization.

Short descriptiontext

Concentric Analgesics is a clinical-stage biopharmaceutical company developing non-opioid pain therapeutics based on a proprietary TRPV1 agonist prodrug platform, with lead asset vocacapsaicin Phase 3-ready for postsurgical pain and pipeline candidates targeting cancer-related and osteoarthritis pain.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-opioid therapeutics, pain management drugs, TRPV1 agonist prodrugs, postsurgical pain treatment, biopharmaceutical drug development
Industry3 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKALAM
Pain Management (Spine & Musculoskeletal)
SECONDARYHLAFABAH
Pain Management Clinics (Interventional & Medical)
Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Non-opioid Pain Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Concentric Analgesics is developing non-opioid pain therapeutics for commercialization. The company has not yet generated revenue and is focused on advancing vocacapsaicin through Phase 3 clinical trials toward NDA submission and eventual commercial launch.

concentricanalgesics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Concentric Analgesics is a clinical-stage biopharmaceutical company developing a portfolio of non-opioid pain therapeutics based on a proprietary TRPV1 agonist prodrug platform. The lead product candidate, vocacapsaicin (CA-008), is a first-in-class water-soluble prodrug that rapidly converts to capsaicin to provide long-lasting, pain-selective analgesia after a single intraoperative local injection, and is Phase 3-ready for postsurgical pain. Pipeline candidates CA-051 (epidural) and CA-011 (intra-articular) extend the platform to chronic refractory cancer/amputation pain and moderate-to-severe osteoarthritis pain, respectively.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 33% reduction in pain AUC 0-96h (p=0.005) and 50% reduction in opioid consumption (p=0.0019) in Phase 2 bunionectomy study
+4 more records
Product overview1 text field

Concentric Analgesics is developing a portfolio of novel non-opioid therapeutic products based on TRPV1 agonist prodrug technology. The company's pipeline consists of three product candidates: Vocacapsaicin (CA-008) as the lead Phase 3-ready program for postsurgical pain, CA-051 for epidural administration targeting cancer and amputation-related chronic refractory pain, and CA-011 as an intra-articular injection for moderate-to-severe osteoarthritis pain. All products leverage a proprietary water-soluble prodrug platform that converts to capsaicin to selectively desensitize pain-conducting nerve fibers without causing numbness or weakness.

Product and service3 records
1Vocacapsaicin (CA-008)
CategoryNon-opioid postsurgical pain therapeutic
Description

Vocacapsaicin (CA-008) is a first-in-class, water-soluble prodrug that rapidly converts to capsaicin (a potent TRPV1 agonist) to provide long-lasting, non-opioid, pain-selective analgesia after a single local injection administered during surgery. It is Phase 3-ready for postsurgical pain management, with FDA Fast Track Designation (December 2017) and FDA Breakthrough Therapy Designation (September 2018); Phase 2 results showed 33% pain reduction and 50% opioid reduction in bunionectomy and 21% pain reduction with 31% opioid reduction in total knee arthroplasty.

2CA-051
CategoryNon-opioid chronic refractory pain therapeutic
Description

CA-051 is a product candidate based on the TRPV1 agonist prodrug platform and designed for epidural administration to treat refractory pain associated with cancer or following amputation, representing the company's chronic refractory pain program.

3CA-011
CategoryNon-opioid osteoarthritis pain therapeutic
Description

CA-011 is a novel intra-articular injection product candidate designed to treat chronic pain associated with moderate to severe osteoarthritis, with a goal of providing 3-6 months of pain relief via a single injection, addressing more than 30 million Americans with osteoarthritis and approximately 5.2 million who currently receive intra-articular injections.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-02
Description

Phase 3 clinical trial partnership with Evolution Research Group, a leading postsurgical pain clinical research site network in the U.S. HD Research LLC, an ERG portfolio company, has conducted prior Phase 2 studies. ERG will conduct registration trials for vocacapsaicin.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-02
Description

Multi-faceted collaboration with URMC, a world-class center in orthopedic surgery products and techniques. URMC will participate in Phase 3 clinical trials and develop innovative methods to capture vocacapsaicin's benefit to patient recovery and rehabilitation. Key investigators include Dr. Michael D. Maloney, Dean's Professor of Orthopaedics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pacira's Exparel (liposomal bupivacaine) is the leading non-opioid, long-acting postsurgical pain product on the market and the most direct competitive benchmark for vocacapsaicin's positioning in surgical centers and hospitals.

TypeDirect peer
Description

Heron developed HTX-011 (bupivacaine/meloxicam extended-release) for postsurgical pain — a directly comparable non-opioid, single-injection surgical pain therapeutic targeting the same orthopedic and soft-tissue surgical settings.

TypeBroad incumbent
Description

Vertex received FDA approval for suzetrigine (VX-548/Journavx) in early 2025 — the first major non-opioid acute pain therapeutic in decades — making it the most consequential broad incumbent now defining the non-opioid pain category vocacapsaicin must compete in.

TypeDirect peer
Description

Trevena developed oliceridine (TRV130), a biased opioid receptor ligand for acute pain in hospital and surgical settings, making it a directly comparable acute/postsurgical pain competitor that has navigated the same FDA pathway.

TypeDirect peer
Description

Anika markets intra-articular hyaluronic acid therapies (e.g., Monovisc, Cingal) for osteoarthritis knee pain — the most directly comparable commercial-stage competitor to Concentric's CA-011 intra-articular OA program.

TypeDirect peer
Description

AcelRx developed Dsuvia (sufentanil sublingual) for acute pain in medically supervised settings, and shares Concentric's CMO (Mike Royal) — making it a directly comparable acute-pain specialty pharmaceutical peer.

TypeDirect peer
Description

Cara Therapeutics developed difelikefalin (Korsuva) for chronic pruritus and is pursuing chronic pain indications — a directly comparable clinical-stage pain therapeutics peer with overlap on Concentric's chronic pain program (CA-051).

TypeEmerging player
Description

SiteOne is developing non-opioid sodium channel (Nav1.7/1.8) inhibitors for acute and chronic pain, representing an emerging non-opioid pain therapeutic competitor in adjacent mechanism space.

TypeBroad incumbent
Description

Pfizer (with Eli Lilly) developed tanezumab, an NGF inhibitor for osteoarthritis and chronic pain — a broad incumbent with a directly comparable OA pain program that overlaps with Concentric's CA-011 intra-articular asset.

TypeEmerging player
Description

Halia Therapeutics is an emerging clinical-stage company developing novel non-opioid therapeutics for pain and inflammation, representing a smaller-scale emerging player in the same non-opioid pain therapeutic category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Concentric Analgesics

Non-opioid Pain Therapeuticsconcentricanalgesics.com

Concentric Analgesics is a clinical-stage biopharmaceutical company developing non-opioid pain therapeutics based on a proprietary TRPV1 agonist prodrug platform, with lead asset vocacapsaicin Phase 3-ready for postsurgical pain and pipeline candidates targeting cancer-related and osteoarthritis pain.

What Concentric Analgesics does

Concentric Analgesics is a clinical-stage biopharmaceutical company developing a portfolio of non-opioid therapeutics for acute and chronic pain management. The company's scientific platform is built on novel TRPV1 agonist prodrug chemistry, in which water-soluble prodrugs are administered locally and then rapidly convert to capsaicin, a TRPV1 receptor agonist. The active metabolite selectively desensitizes pain-conducting C-fiber nociceptors, producing durable analgesia without the sensory numbness or motor weakness characteristic of local anesthetics or regional nerve blocks. The pipeline comprises three product candidates: vocacapsaicin (CA-008), the lead Phase 3-ready program targeting postsurgical pain via a single intraoperative injection with durable relief of two weeks or more; CA-051, an epidural formulation for chronic refractory cancer pain and post-amputation pain; and CA-011, an intra-articular injection targeting 3-6 months of relief in moderate-to-severe knee osteoarthritis, an addressable population of more than 14 million Americans.

Vocacapsaicin carries both FDA Fast Track Designation (December 2017) and FDA Breakthrough Therapy Designation (September 2018), and positive Phase 2 data have been generated across bunionectomy (33% pain reduction, 50% opioid consumption reduction), total knee arthroplasty (21% pain reduction, 31% opioid reduction through 168 hours, 52% opioid reduction after discharge), and open laparotomy indications. Phase 2 results were published on the cover of the August 2024 issue of ANESTHESIOLOGY. The company has formalized Phase 3 clinical partnerships with Evolution Research Group (a U.S. postsurgical pain site network) and the University of Rochester Medical Center for registration trials.

Concentric Analgesics operates a clinical-stage business model with no commercial revenue today; near-term economics depend on advancing vocacapsaicin through Phase 3, NDA filing, and eventual commercialization. Future commercialization is expected to follow an enterprise field sales model targeting hospitals, ambulatory surgical centers, anesthesiologists, and orthopedic surgeons for the postsurgical indication, with broader applicability to oncology pain management and osteoarthritis workflows. The company is headquartered in the San Francisco Bay Area, was founded in 2014 (per firmographic records) / 2017 (per company-history records), and has raised approximately $96 million in total equity and convertible financing from institutional investors including Oracle Investment Management, Venrock Healthcare Capital Partners, Cowen Healthcare Investments, Kern Whelan Capital, and Incisive Capital. Headcount is in the 11-50 range, consistent with a lean clinical-development-stage organization.

Concentric Analgesics firmographics

Firmographics
Name
Concentric Analgesics
Legal name
Concentric Analgesics, Inc.
Website
https://concentricanalgesics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Concentric Analgesics is a clinical-stage biopharmaceutical company developing non-opioid pain therapeutics based on a proprietary TRPV1 agonist prodrug platform, with lead asset vocacapsaicin Phase 3-ready for postsurgical pain and pipeline candidates targeting cancer-related and osteoarthritis pain.
Ownership category
akta.pro rank

Concentric Analgesics industry classification

Industry
Product category
Non-opioid Pain Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKALAM
Pain Management (Spine & Musculoskeletal)
SECONDARYHLAFABAH
Pain Management Clinics (Interventional & Medical)
Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers

Keywords

  • Non-opioid therapeutics
  • Pain management drugs
  • TRPV1 agonist prodrugs
  • Postsurgical pain treatment
  • Biopharmaceutical drug development

Where Concentric Analgesics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Concentric Analgesics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: As a clinical-stage biopharmaceutical company, Concentric Analgesics is developing non-opioid pain therapeutics for commercialization. The company has not yet generated revenue and is focused on advancing vocacapsaicin through Phase 3 clinical trials toward NDA submission and eventual commercial launch.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Concentric Analgesics product offering

Product offering

Core offering

Concentric Analgesics is a clinical-stage biopharmaceutical company developing a portfolio of non-opioid pain therapeutics based on a proprietary TRPV1 agonist prodrug platform. The lead product candidate, vocacapsaicin (CA-008), is a first-in-class water-soluble prodrug that rapidly converts to capsaicin to provide long-lasting, pain-selective analgesia after a single intraoperative local injection, and is Phase 3-ready for postsurgical pain. Pipeline candidates CA-051 (epidural) and CA-011 (intra-articular) extend the platform to chronic refractory cancer/amputation pain and moderate-to-severe osteoarthritis pain, respectively.

Product overview

Concentric Analgesics is developing a portfolio of novel non-opioid therapeutic products based on TRPV1 agonist prodrug technology. The company's pipeline consists of three product candidates: Vocacapsaicin (CA-008) as the lead Phase 3-ready program for postsurgical pain, CA-051 for epidural administration targeting cancer and amputation-related chronic refractory pain, and CA-011 as an intra-articular injection for moderate-to-severe osteoarthritis pain. All products leverage a proprietary water-soluble prodrug platform that converts to capsaicin to selectively desensitize pain-conducting nerve fibers without causing numbness or weakness.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vocacapsaicin (CA-008) Vocacapsaicin (CA-008) is a first-in-class, water-soluble prodrug that rapidly converts to capsaicin (a potent TRPV1 agonist) to provide long-lasting, non-opioid, pain-selective analgesia after a single local injection administered during surgery. It is Phase 3-ready for postsurgical pain management, with FDA Fast Track Designation (December 2017) and FDA Breakthrough Therapy Designation (September 2018); Phase 2 results showed 33% pain reduction and 50% opioid reduction in bunionectomy and 21% pain reduction with 31% opioid reduction in total knee arthroplasty.
  • CA-051 CA-051 is a product candidate based on the TRPV1 agonist prodrug platform and designed for epidural administration to treat refractory pain associated with cancer or following amputation, representing the company's chronic refractory pain program.
  • CA-011 CA-011 is a novel intra-articular injection product candidate designed to treat chronic pain associated with moderate to severe osteoarthritis, with a goal of providing 3-6 months of pain relief via a single injection, addressing more than 30 million Americans with osteoarthritis and approximately 5.2 million who currently receive intra-articular injections.

Quantifiable outcome

  • 33% reduction in pain AUC 0-96h (p=0.005) and 50% reduction in opioid consumption (p=0.0019) in Phase 2 bunionectomy study
  • +4 more outcomes

Companies that use Concentric Analgesics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Concentric Analgesics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Concentric Analgesics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Evolution Research Group (ERG)coreStrategic or Co-development Partner · 2 February 2022Phase 3 clinical trial partnership with Evolution Research Group, a leading postsurgical pain clinical research site network in the U.S. HD Research LLC, an ERG portfolio company, has conducted prior Phase 2 studies. ERG will conduct registration trials for vocacapsaicin.
  • University of Rochester Medical Center (URMC)coreStrategic or Co-development Partner · 2 February 2022Multi-faceted collaboration with URMC, a world-class center in orthopedic surgery products and techniques. URMC will participate in Phase 3 clinical trials and develop innovative methods to capture vocacapsaicin's benefit to patient recovery and rehabilitation. Key investigators include Dr. Michael D. Maloney, Dean's Professor of Orthopaedics.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Concentric Analgesics competitors and assessment

Company assessment

Direct peers

  • Pacira BioSciences: Pacira's Exparel (liposomal bupivacaine) is the leading non-opioid, long-acting postsurgical pain product on the market and the most direct competitive benchmark for vocacapsaicin's positioning in surgical centers and hospitals.
  • Heron Therapeutics: Heron developed HTX-011 (bupivacaine/meloxicam extended-release) for postsurgical pain — a directly comparable non-opioid, single-injection surgical pain therapeutic targeting the same orthopedic and soft-tissue surgical settings.
  • Trevena: Trevena developed oliceridine (TRV130), a biased opioid receptor ligand for acute pain in hospital and surgical settings, making it a directly comparable acute/postsurgical pain competitor that has navigated the same FDA pathway.
  • Anika Therapeutics: Anika markets intra-articular hyaluronic acid therapies (e.g., Monovisc, Cingal) for osteoarthritis knee pain — the most directly comparable commercial-stage competitor to Concentric's CA-011 intra-articular OA program.
  • AcelRx Pharmaceuticals: AcelRx developed Dsuvia (sufentanil sublingual) for acute pain in medically supervised settings, and shares Concentric's CMO (Mike Royal) — making it a directly comparable acute-pain specialty pharmaceutical peer.
  • Cara Therapeutics: Cara Therapeutics developed difelikefalin (Korsuva) for chronic pruritus and is pursuing chronic pain indications — a directly comparable clinical-stage pain therapeutics peer with overlap on Concentric's chronic pain program (CA-051).

Broad incumbents

  • Vertex Pharmaceuticals: Vertex received FDA approval for suzetrigine (VX-548/Journavx) in early 2025 — the first major non-opioid acute pain therapeutic in decades — making it the most consequential broad incumbent now defining the non-opioid pain category vocacapsaicin must compete in.
  • Pfizer: Pfizer (with Eli Lilly) developed tanezumab, an NGF inhibitor for osteoarthritis and chronic pain — a broad incumbent with a directly comparable OA pain program that overlaps with Concentric's CA-011 intra-articular asset.

Emerging players

  • SiteOne Therapeutics: SiteOne is developing non-opioid sodium channel (Nav1.7/1.8) inhibitors for acute and chronic pain, representing an emerging non-opioid pain therapeutic competitor in adjacent mechanism space.
  • Halia Therapeutics: Halia Therapeutics is an emerging clinical-stage company developing novel non-opioid therapeutics for pain and inflammation, representing a smaller-scale emerging player in the same non-opioid pain therapeutic category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Concentric Analgesics social profiles

Digital presence

Concentric Analgesics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Concentric Analgesics leadership team

Management profile

Number of profiles

Profiles8 records

Concentric Analgesics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Concentric Analgesics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Concentric Analgesics

What does Concentric Analgesics do?

Concentric Analgesics is a clinical-stage biopharmaceutical company developing a portfolio of non-opioid pain therapeutics based on a proprietary TRPV1 agonist prodrug platform. The lead product candidate, vocacapsaicin (CA-008), is a first-in-class water-soluble prodrug that rapidly converts to capsaicin to provide long-lasting, pain-selective analgesia after a single intraoperative local injection, and is Phase 3-ready for postsurgical pain. Pipeline candidates CA-051 (epidural) and CA-011 (intra-articular) extend the platform to chronic refractory cancer/amputation pain and moderate-to-severe osteoarthritis pain, respectively.

Is Concentric Analgesics a public or private company?

Concentric Analgesics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Concentric Analgesics founded?

Concentric Analgesics was founded in 2017. It employs 1 to 10 people.

Where is Concentric Analgesics based?

Concentric Analgesics is headquartered in San Francisco, United States, in the North America region.

How does Concentric Analgesics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Concentric Analgesics's main competitors?

Direct peers on record are Pacira BioSciences, Heron Therapeutics, Trevena, Anika Therapeutics, AcelRx Pharmaceuticals and Cara Therapeutics. Broad incumbents are Vertex Pharmaceuticals and Pfizer. Emerging players are SiteOne Therapeutics and Halia Therapeutics.

Does Concentric Analgesics have an API?

No public API is recorded for Concentric Analgesics.

What industry is Concentric Analgesics in?

Concentric Analgesics's product category is Non-opioid Pain Therapeutics. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAKALAM, Pain Management (Spine & Musculoskeletal). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WorkinbiotechConcentric AnalgesicsConcentric Analgesics, founded in 2014 and based in San Francisco, is advancing its investigational product, CA-008, into Phase 3 clinical studies for treating postsurgical pain. This drug is a water-soluble prodrug of capsaicin designed to desensitize pain-conducting nerve fibers, aiming to provide a non-opioid solution to pain management. The company focuses on developing long-lasting, site-specific, and pain-selective therapies to reduce dependency on traditional opioids.EIN PresswirePostoperative Pain Treatment Market to Experience Robust Growth by 2034 | Analysis by DelveInsightDelveInsight's report forecasts robust growth in the postoperative pain treatment market through 2034, with 67 million incident cases in 2023 across the 7MM. The US accounted for 60.41% of cases, and the market was valued at USD 2,979 million in 2023. Emerging therapies and increased awareness are expected to drive growth.EIN PresswireGlobal Analgesics Market Outlook 2024-2033: Growth Drivers, Share, And TrendsThe global analgesics market is projected to grow from $106.57 billion in 2023 to $110.76 billion in 2024, a 3.9% CAGR, and reach $128.18 billion by 2028 at 3.7% CAGR. Growth is driven by chronic disease prevalence, alternative therapies, and market competition, with North America leading and the Middle East expected to outpace other regions.DAZ.onlineCapsaicin-Prodrug gegen postoperative Schmerzen eingesetztConcentric Analgesics' Vocacapsaicin, a capsaicin prodrug, reduced postoperative pain in a Phase-II study of 147 patients. The highest dose (0.3 mg/ml) cut resting pain by 33% and reduced opioid use by 23 hours. The FDA granted breakthrough therapy status, and a Phase-III study is planned.ClinicaltrialvanguardConcentric Analgesics Data Unveils Extended Pain Relief and Reduced Opioid UseConcentric Analgesics presented clinical data for vocacapsaicin at the IASP World Congress, showing reduced opioid use in patients undergoing total knee arthroplasty and bunionectomy. In bunionectomy, 5 days earlier opioid discontinuation versus 16% in placebo, and 50% fewer patients needed opioids after two weeks in knee arthroplasty. The findings support potential for opioid dependence reduction, especially with the NO PAIN Act.YahooConcentric Analgesics highlights data on vocacapsaicin for pain reliefConcentric Analgesics will present Phase II data on vocacapsaicin at the IASP World Congress, showing 38% of patients required opioids two weeks after total knee arthroplasty versus 58% in placebo. The company plans four more studies, with the first three FDA-cleared, and is seeking commercial partnerships.YahooConcentric Analgesics highlights data on vocacapsaicin for pain reliefConcentric Analgesics will present Phase II data on vocacapsaicin at the IASP World Congress, showing 38% of patients required opioids two weeks after total knee arthroplasty versus 58% in placebo. The drug also enabled opioid cessation by day 5 after bunionectomy, and the company plans four more studies, with the first three FDA-cleared.ConcentricanalgesicsAnnouncing Data Highlighting Two Weeks of Durable Pain Relief and Earlier Cessation of Opioids — Concentric Analgesics, Inc.Concentric Analgesics announced a poster presentation at the IASP World Congress in Amsterdam on August 6, 2024, showing vocacapsaicin produced two weeks of postsurgical analgesia and earlier opioid cessation after total knee arthroplasty and bunionectomy. In the bunionectomy trial, all vocacapsaicin patients stopped opioids by day 5 versus 16% of placebo; at two weeks, 58% of placebo versus 38% of vocacapsaicin patients still required opioids. The company plans Phase 3 studies.ConcentricanalgesicsConcentric Analgesics Announces Peer-Reviewed Publication of Positive Phase 2 Clinical Data — Concentric Analgesics, Inc.Concentric Analgesics announced on July 24, 2024 that a multicenter, randomized Phase 2 trial of vocacapsaicin was published on the cover of ANESTHESIOLOGY's August 2024 issue. The 147-patient study found a 33% pain reduction at rest over Days 0–5, 37% over Days 0–8, 50% less opioid use, and 26% of vocacapsaicin patients never needed postoperative opioids versus 5% placebo. Phase 3 trials are underway.ConcentricanalgesicsAbout — Concentric Analgesics, Inc.Concentric Analgesics, Inc., a private biopharmaceutical company founded in 2014 and based in San Francisco, develops non-opioid pain therapeutics targeting acute and chronic pain. Its portfolio includes three indications: postsurgical pain, chronic osteoarthritis pain and refractory pain, each led by a prodrug that converts to capsaicin. Vocacapsaicin (CA-008) is Phase-3 ready and holds FDA Fast Track and Breakthrough Therapy Designations.